David Domzalski - Rockwell Medical Director
RMTI Stock | USD 1.64 0.01 0.61% |
Director
Mr. David T. Domzalski is an Independent Director of Rockwell Medical, Inc. Mr. Domzalski currently serves as President of the U.S. subsidiary of Foamix Pharmaceuticals Inc., a position he has held since April 2014. Prior to his tenure at Foamix, Mr. Domzalski was Vice President of Sales Marketing, at LEO Pharma, Inc. where he led the efforts to design and buildout the U.S. commercial operations, overseeing approximately 200 employees across multiple functional areas. He successfully managed the turnaround of Leo Pharmas psoriasis franchise from a 2year prescription decline to an annual growth of 26. Mr. Domzalski was responsible for the strategic relaunch of Taclonex Topical Suspension which resulted in Taclonex being reestablished as the number one brand in the category. Prior to LEO Pharma, Mr. Domzalski was the Senior Vice President and General Manager of the Womens Health Urology division of Azur Pharma, where he had full PL responsibility for a startup business unit. Before Azur, Mr. Domzalski spent 5 years from 2003 to 2008 as the Vice President of Sales Marketing for Warner Chilcott, where he directed all commercial efforts for inline brands focused on therapeutic areas of dermatology, womens health and urology. His achievements at Warner Chilcott included the launch of four products within a twelve month period, including Taclonex for psoriasis and Doryx Tablets for acne since 2017.
Age | 49 |
Tenure | 7 years |
Address | 30142 South Wixom road, Wixom, MI, United States, 48393 |
Phone | 248 960 9009 |
Web | https://www.rockwellmed.com |
Rockwell Medical Management Efficiency
The company has return on total asset (ROA) of (0.0844) % which means that it has lost $0.0844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4768) %, meaning that it created substantial loss on money invested by shareholders. Rockwell Medical's management efficiency ratios could be used to measure how well Rockwell Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to -0.2. The current Return On Assets is estimated to decrease to -0.17. As of now, Rockwell Medical's Total Current Assets are increasing as compared to previous years. The Rockwell Medical's current Intangible Assets is estimated to increase to about 13 M, while Total Assets are projected to decrease to under 37.3 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Solomon Mayer | Microbot Medical | 62 | |
David Urban | FSD Pharma Class | N/A | |
Donal Carroll | FSD Pharma Class | 42 | |
Alfred Lim | EUDA Health Holdings | 72 | |
Jun Zheng | China SXT Pharmaceuticals | 46 | |
Vladimir Klacar | FSD Pharma Class | N/A | |
Will Santana | PetIQ Inc | 45 | |
Moshe Shoham | Microbot Medical | 64 | |
Antaine Furlong | FSD Pharma Class | 40 | |
Martin Madden | Microbot Medical | 57 | |
Yoav Waizer | Microbot Medical | 51 | |
James Clarke | PetIQ Inc | 45 | |
Scott Huff | PetIQ Inc | 46 | |
Susan Sholtis | PetIQ Inc | 51 | |
Scott Burell | Microbot Medical | 52 | |
Mark First | PetIQ Inc | 53 | |
Ronald Kennedy | PetIQ Inc | 71 | |
Yoseph Bornstein | Microbot Medical | 65 | |
Gerald Goldberg | FSD Pharma Class | 70 | |
Prattipati Laxminarain | Microbot Medical | 59 | |
Gary Michael | PetIQ Inc | 77 |
Management Performance
Return On Equity | -0.48 | ||||
Return On Asset | -0.0844 |
Rockwell Medical Leadership Team
Elected by the shareholders, the Rockwell Medical's board of directors comprises two types of representatives: Rockwell Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rockwell. The board's role is to monitor Rockwell Medical's management team and ensure that shareholders' interests are well served. Rockwell Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rockwell Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Cooper, Director | ||
David Domzalski, Director | ||
Angus Smith, Principal Financial Officer | ||
Thomas Klema, CFO, Vice President Treasurer, Secretary | ||
Mark Strobeck, CEO President | ||
Marc MD, Chief Officer | ||
James McCarthy, Senior Development | ||
Timothy Chole, Senior Marketing | ||
Mark Ravich, Director | ||
Michael DeYoung, Vice President - Operations | ||
Kenneth Holt, Independent Director | ||
Benjamin Wolin, Chairman of the Board | ||
Paul McGarry, Principal Accounting Officer, Vice President Corporate Controller | ||
Megan Timmins, Chief VP | ||
Patrick Bagley, Independent Director | ||
David Kull, Principal Accounting Officer | ||
Jim McCarthy, Senior Vice President - Corporate and Business Development | ||
Jason Finkelstein, Investor Representative | ||
Ajay Gupta, Chief Scientific Officer | ||
Ronald Boyd, Independent Director | ||
Lisa Colleran, Director | ||
Jesse Neri, Senior Finance | ||
Charlie Shiner, Vice President of Marketing | ||
Raymond Pratt, Chief Medical Officer | ||
Robin Smith, Director | ||
Robert Chioini, Founder, Chairman of The Board and CEO | ||
Heather Hunter, Senior Officer | ||
Michael Rice, Co-Founder, LifeSci Advisors, LLC | ||
Stuart Paul, CEO, Director |
Rockwell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rockwell Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.48 | ||||
Return On Asset | -0.0844 | ||||
Profit Margin | (0.10) % | ||||
Operating Margin | (0.02) % | ||||
Current Valuation | 50.91 M | ||||
Shares Outstanding | 29.33 M | ||||
Shares Owned By Insiders | 3.00 % | ||||
Shares Owned By Institutions | 17.49 % | ||||
Number Of Shares Shorted | 569.54 K | ||||
Price To Earning | (14.72) X |
Currently Active Assets on Macroaxis
When determining whether Rockwell Medical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rockwell Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rockwell Medical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rockwell Medical Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rockwell Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Rockwell Stock please use our How to Invest in Rockwell Medical guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Rockwell Stock analysis
When running Rockwell Medical's price analysis, check to measure Rockwell Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rockwell Medical is operating at the current time. Most of Rockwell Medical's value examination focuses on studying past and present price action to predict the probability of Rockwell Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rockwell Medical's price. Additionally, you may evaluate how the addition of Rockwell Medical to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Rockwell Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rockwell Medical. If investors know Rockwell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rockwell Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 3.585 | Quarterly Revenue Growth 0.144 | Return On Assets (0.08) | Return On Equity (0.48) |
The market value of Rockwell Medical is measured differently than its book value, which is the value of Rockwell that is recorded on the company's balance sheet. Investors also form their own opinion of Rockwell Medical's value that differs from its market value or its book value, called intrinsic value, which is Rockwell Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rockwell Medical's market value can be influenced by many factors that don't directly affect Rockwell Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rockwell Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rockwell Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rockwell Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.